Anupam Rasayan India Limited has informed the Exchange regarding a press release to be issued by the Company, today i.e., May 23, 2026, regarding the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026.
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anupam Rasayan reported strong FY26 results with total revenue of Rs 23,836 Mn, up 65% YoY from Rs 14,485 Mn. PAT grew 39% to Rs 2,222 Mn from Rs 1,600 Mn. However, EBITDA margin compressed to 23% from 28% in FY25 due to Q4 weakness - Q4 EBITDA fell 6% YoY and PAT dropped 11% despite 26% revenue growth in the quarter. The company highlighted landmark achievements including its highest-ever annual sales and cash flow, successful acquisition of Jayhawk Fine Chemicals (US) delivering proforma revenue of US$95 Mn, and signing a definitive agreement to acquire Bliss GVS Pharma to strengthen its pharmaceutical value chain.
While full-year revenue and profit growth exceeded expectations, the Q4 margin compression and profit decline despite strong revenue growth raises concerns about cost pressures. Shareholders should monitor if the margin compression is temporary or structural as the company integrates recent acquisitions.